Results 1 to 10 of about 434,960 (396)
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Nature Medicine, 2021 Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
Tina Schmidt, David Schub, Janine Mihm
exaly +2 more sources
Nature Medicine, 2022 The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines.
Donghui Lu +2 more
exaly +2 more sources
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Nature, 2021 Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 ...
Nicolas Guibert +2 more
exaly +2 more sources
Nature Medicine, 2022 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who
Jingxin Li, Lihua Hou, Pengfei Jin
exaly +2 more sources
Heterologous carriers in the anamnestic antihapten response [PDF]
, 1968 Anamnestic antihapten responses were obtained to trinitrophenyl (TNP) when rabbits sensitized to trinitrophenyl-hemocyanin (TNP-KLH) were challenged with TNP-heterologous protein conjugates.
Campbell, Dan H., Rittenberg, Marvin B.
core +4 more sources
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
Vaccines, 2021 Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the global challenge. Reaching global herd immunity will help end the COVID-19 pandemic.
Tzu-Chuan Ho +8 more
doaj +2 more sources
Human Vaccines & Immunotherapeutics, 2022 In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity
Nasamon Wanlapakorn +11 more
doaj +2 more sources
Nature Communications, 2021 Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities.
Kai Hu +2 more
exaly +2 more sources
Past Life and Future Effects—How Heterologous Infections Alter Immunity to Influenza Viruses
Frontiers in Immunology, 2018 Influenza virus frequently mutates due to its error-prone polymerase. This feature contributes to influenza virus’s ability to evade pre-existing immunity, leading to annual epidemics and periodic pandemics.
Aisha Souquette, Paul G Thomas
exaly +3 more sources
Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections
Frontiers in Immunology, 2019 The central paradigm of vaccination is to generate resistance to infection by a specific pathogen when the vacinee is re-exposed to that pathogen. This paradigm is based on two fundamental characteristics of the adaptive immune system, specificity and ...
Babita Agrawal, Kaihu Yao
exaly +2 more sources